Fenaux, Pierre <br/><br/>
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.  [electronic resource] 

 -  The New England journal of medicine  01 2020 
 - 140-151 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1908892  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Activin Receptors, Type II--adverse effects<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anemia, Sideroblastic--drug therapy<br/>Double-Blind Method<br/>Erythrocyte Transfusion<br/>Female<br/>Hematinics--adverse effects<br/>Hemoglobins--analysis<br/>Humans<br/>Immunoglobulin Fc Fragments--adverse effects<br/>Infusions, Subcutaneous<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Recombinant Fusion Proteins--adverse effects